BB-2983

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBB-2983
Drug Alias NameBB-2983GI-245402
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeptide hydrolase inhibitorsMatrix metalloproteinase inhibitorsTumor necrosis factor inhibitors
TargetsMatrix metalloproteinasePeptide hydrolaseTumor necrosis factor
Therapy Area/IndicationsInflammatory Bowel DiseasesRheumatic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcVernalis Plc
Active IndicationsN/A
Inactive IndicationsInflammatory Bowel DiseasesRheumatic Diseases

Other Information

ATC CodeN/A
Related LinksN/A